LSI Stock Chart & Stats
€0.10
€0.00(0.00%)
At close: 4:00 PM EST
€0.10
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.06 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€589.88M
Enterprise Value€11.92K
Total Cash (Recent Filing)€535.65M
Total Debt (Recent Filing)€6.83B
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Mar 16, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding9,611,072,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)2.09
Price to Sales (P/S)1.46
P/FCF Ratio-28.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Life-sciences PlatformA portfolio spanning agriculture and environmental applications, supported by in-house R&D and multiple-market subsidiaries, provides diversification and creates durable opportunities to commercialize biological and biotechnology solutions.
Meaningful Equity And Stable Asset BaseThe sizable equity base and stable assets provide a substantial operating foundation, which may help the company absorb near-term losses and fund restructuring or product development despite elevated leverage.
Established Operating Cash-flow HistorySeveral years of positive operating cash flow indicate that the underlying businesses have previously converted operations into cash, offering evidence of an established commercial base even though 2025 marked a significant reversal.
Bears Say
Severe Margin And Profitability DeteriorationThe sharp margin contraction and move into operating losses weaken earnings quality and suggest pressure from costs, pricing or product mix. Sustained losses could restrict investment capacity and delay recovery in shareholder returns.
Negative Cash GenerationThe reversal from consistently positive operating cash flow to negative cash generation reduces financial flexibility. A large free-cash-flow outflow may require additional funding and could constrain R&D, commercialization and other growth initiatives.
Elevated And Rising LeverageHigh leverage increases balance-sheet sensitivity while profitability and cash generation are weak. Greater debt obligations can limit strategic flexibility, raise refinancing dependence and amplify the impact of continued operating losses.
CK Life Sciences International (Holdings), Inc. News
LSI FAQ
What was CK Life Sciences International (Holdings), Inc.’s price range in the past 12 months?
CK Life Sciences International (Holdings), Inc. lowest stock price was €0.06 and its highest was €0.11 in the past 12 months.
What is CK Life Sciences International (Holdings), Inc.’s market cap?
CK Life Sciences International (Holdings), Inc.’s market cap is €589.88M.
When is CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date?
CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date is Mar 16, 2027 which is in 187 days.
How were CK Life Sciences International (Holdings), Inc.’s earnings last quarter?
CK Life Sciences International (Holdings), Inc. released its earnings results on Aug 11, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is CK Life Sciences International (Holdings), Inc. overvalued?
According to Wall Street analysts CK Life Sciences International (Holdings), Inc.’s price is currently Overvalued.
Does CK Life Sciences International (Holdings), Inc. pay dividends?
CK Life Sciences International (Holdings), Inc. does not currently pay dividends.
What is CK Life Sciences International (Holdings), Inc.’s EPS estimate?
CK Life Sciences International (Holdings), Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CK Life Sciences International (Holdings), Inc. have?
CK Life Sciences International (Holdings), Inc. has 9,611,072,000 shares outstanding.
What happened to CK Life Sciences International (Holdings), Inc.’s price movement after its last earnings report?
CK Life Sciences International (Holdings), Inc. reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went down -1.613%.
Which hedge fund is a major shareholder of CK Life Sciences International (Holdings), Inc.?
Currently, no hedge funds are holding shares in DE:LSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CK Life Sciences International (Holdings), Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceuticals and agriculture related business. It operates through the following segments: Agriculture-Related and Health. The company was founded on August 10, 2001 and is headquartered in Hong Kong.
Technical Analysis
Sino Biopharmaceutical
―
Ascletis Pharma, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―